1,463 results on '"Moliterno, David"'
Search Results
252. Little Kids, Little Problems—Big Kids, Big Problems
253. Be Careful What You Read and the Company You Keep
254. The Value of Focus
255. A Letter to the (Founding) Editor
256. JACC: Cardiovascular Interventions 2.0
257. WHITE BLOOD CELL COUNT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION IN THE CONTEMPORARY ERA: INSIGHTS FROM THE PARIS STUDY
258. More Time to SORT OUT Clinical Outcomes After First-Generation Drug-Eluting Stents
259. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial
260. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
261. TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry
262. TCT-219 Influence Of Anemia On Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention
263. TCT-206 Tailoring the Intensity of Antiplatelet Pharmacotherapy to Ischemic and Bleeding Risk: A Cost Optimizing Simulation From PARIS
264. TCT-205 Incidence and clinical outcomes associated with DAPT discontinuation in complex PCI patients: From the PARIS registry
265. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.
266. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
267. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. (Correspondence)
268. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials
269. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans
270. Toward a More Interactive Central Illustration.
271. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry
272. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial
273. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial
274. Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
275. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention
276. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents
277. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents
278. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes
279. Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis
280. CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRACER TRIAL
281. Sudden Cardiac Death After Non–ST-Segment Elevation Acute Coronary Syndrome
282. TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL
283. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar
284. Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
285. Abstract 16820: Albuminuria and Outcomes in Patients With Non-ST-segment Elevation Acute Coronary Syndromes: Results From the TRACER Trial
286. Ageless benefits of transradial access for percutaneous coronary revascularization
287. TCT-225 Impact of Age on the Disruption of Dual Antiplatelet Therapy: Analysis from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented) Patients Registry
288. Year 1: A Short Look Back and a Long Look Forward
289. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
290. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.
291. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet...
292. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
293. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials
294. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients
295. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
296. Bifurcation Stenting Techniques and Outcomes in Patients With Stable Coronary Artery Disease
297. PATTERNS OF ADHERENCE TO DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING COMPLEX PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE PARIS REGISTRY
298. IMPACT OF AGE ON THE MODES OF DUAL ANTIPLATELET THERAPY CESSATION: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY
299. Potential Hazards of Adding Nonsteroidal Anti-inflammatory Drugs to Antithrombotic Therapy After Myocardial Infarction
300. Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.